Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Risk Management Plan Proposes Three Categories of Tools

This article was originally published in The Pink Sheet Daily

Executive Summary

Draft guidance establishes targeted education and outreach, reminder systems, and performance-linked access systems as three categories of risk minimization tools. The draft drops a concept paper proposal that would have grouped drugs into one of four tiers of risk management programs.
Advertisement

Related Content

FDA Should Create Separate Division To Review Drug-Induced Liver Toxicity – Consultant
FDA Should Create Separate Division To Review Drug-Induced Liver Toxicity – Consultant
Solvay Cilansetron NDA Filing Will Feature "Appropriate Use Plan" For Irritable Bowel Syndrome Drug
Solvay Cilansetron NDA Filing Will Feature "Appropriate Use Plan" For Irritable Bowel Syndrome Drug

Topics

Advertisement
UsernamePublicRestriction

Register

PS059570

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel